中德临床肿瘤学杂志(英文版)2004，Vol.3Issue(2)：90-92,3.
来曲唑与氨鲁米特对照治疗绝经后晚期乳腺癌113例
Comparison of Letrozole and Aminoglutethimide in Treatment of 113 Cases of Postmenopausal Women with Advanced Breast Cancer
刘冬耕 1管忠震 1沈镇宙 1韩企夏 1宋三泰 1刘晓晴1
作者信息
- 1. 广州中山医科大学附属肿瘤医院,510060
- 折叠
摘要
Abstract
Objective: To compare the efficacy and tolerability of letrozole with aminoglutethimide (AG) in postmenopausal women with advanced breast cancer. Methods: The multicenter, randomized controlled clinical trial was conducted in 113 patients. They randomly received letrozole 2.5 mg once daily (letrozole group) or AG 250 mg 4 times daily (AG group) with hydrocortisone. Results: The OR in letrozole group was 23.73% (2 cases of CR and 12 cases of PR, ITT OR was 21.88%), which was higher than in AG group(the OR 11.11%, 1 case of CR and 5 cases of PR, ITT 10.17%), but there was no statistically significant difference (P＞0.05). Adverse events (AE) and the treatment related AE (RAE) in letrozole group (n=59) was 18.54 % and 13.56 % respectively, significantly lower than those (42.11% and 33.33% respectively) in AG group (n=57, P=0.002). Conclusion: The OR of letrozole in the treatment of postmenopausal advanced breast cancer positive or unknown for hormonal receptor is 23.73%, showing no significant difference to that of AG. The AE of letrozole are significantly less than AG.关键词
来曲唑/氨鲁米特/晚期乳腺癌Key words
letrozole/aminoglutethimide/advanced breast cancer分类
医药卫生引用本文复制引用
刘冬耕,管忠震,沈镇宙,韩企夏,宋三泰,刘晓晴..来曲唑与氨鲁米特对照治疗绝经后晚期乳腺癌113例[J].中德临床肿瘤学杂志(英文版),2004,3(2):90-92,3.
